Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?

Cardiovasc Res. 2009 Dec 1;84(3):341-2. doi: 10.1093/cvr/cvp339. Epub 2009 Oct 9.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Amides / adverse effects
  • Amides / therapeutic use
  • Animals
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Atherosclerosis / physiopathology*
  • Cannabinoid Receptor Modulators / physiology*
  • Disease Models, Animal
  • Endocannabinoids*
  • Humans
  • Macrophages / metabolism
  • Mice
  • Piperidines / adverse effects
  • Piperidines / therapeutic use
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Reactive Oxygen Species / metabolism
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB1 / physiology
  • Receptor, Cannabinoid, CB2 / antagonists & inhibitors
  • Receptor, Cannabinoid, CB2 / physiology
  • Rimonabant
  • Signal Transduction / physiology*

Substances

  • Amides
  • Cannabinoid Receptor Modulators
  • Endocannabinoids
  • Piperidines
  • Pyrazoles
  • Pyridines
  • Reactive Oxygen Species
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • Rimonabant
  • N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide